Biowaiver: waiver of an in vivo bioequivalence study

A biowaiver lets an applicant replace an in vivo bioequivalence study with in vitro data, for BCS Class I and III substances or additional strengths.

Also known as: BCS-based biowaiver, BCS biowaiver, additional strength biowaiver

3 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

BCS guidance
ICH M9, applied in the EU since 30 July 2020
Eligible classes
BCS Class I and III substances in immediate-release oral forms
Additional strengths
EMA bioequivalence guideline; ICH M13B from 17 March 2027
Excluded
Narrow therapeutic index drugs, for the BCS route

How it works

A biowaiver is a regulator's acceptance that an in vivo bioequivalence study is not needed, because in vitro data and the properties of the substance or the formulation give enough assurance of equivalent performance. EU practice knows two main kinds. The BCS-based biowaiver rests on the Biopharmaceutics Classification System and replaces the study for the product as a whole. The additional-strength biowaiver extends the result of a study on one strength to the other strengths of the same product. Both are used mainly in generic and hybrid applications and in variations that change composition or manufacture.

BCS-based biowaivers follow ICH M9, which has applied in the EU since 30 July 2020 and replaced Appendix III of EMA's bioequivalence guideline. It covers immediate-release solid oral dosage forms and suspensions that deliver the substance to the systemic circulation. The substance must be highly soluble, meaning that the highest single therapeutic dose dissolves in 250 ml or less across pH 1.2 to 6.8, and either highly permeable (Class I) or not (Class III). Test and reference must then dissolve comparably: very rapidly, at least 85% in 15 minutes, or for Class I rapidly, at least 85% in 30 minutes with similar profiles. Excipient rules are stricter for Class III, where the formulation must be qualitatively the same as the reference and quantitatively very similar. Narrow therapeutic index drugs are excluded, and so are products absorbed in the mouth.

For additional strengths, the EMA guideline allows a study on one strength, normally the highest, to cover the others when all strengths are made by the same process, have the same qualitative composition and a proportional quantitative composition, and show similar dissolution profiles. Which strength must be studied depends on whether the pharmacokinetics are linear over the dose range, and where the conditions are only partly met a bracketing approach with studies on the extreme strengths may be accepted. ICH M13B, published by EMA in September 2026, harmonises the additional-strength biowaiver for immediate-release solid oral forms and takes over from the EMA guideline's provisions when it comes into effect on 17 March 2027. Simpler waivers exist for aqueous oral solutions and for parenteral solutions with the same active substance and comparable excipients.

What goes wrong

A solubility study that does not cover the highest single dose in the SmPC or the full pH range; permeability claimed from literature that does not meet the guideline's standard; excipients such as sorbitol, mannitol or surfactants that differ from the reference and can affect absorption; dissolution compared with an unsuitable method, or an f2 similarity factor calculated on profiles it should not be used for; and strength biowaivers claimed for formulations that are not proportional. A biowaiver refused during the procedure leaves the applicant to run the study inside a clock-stop, which is rarely possible.

Biowaiver: common questions

Which drugs qualify for a BCS-based biowaiver?

Under ICH M9, substances in BCS Class I (high solubility, high permeability) and Class III (high solubility, low permeability), formulated as immediate-release solid oral forms or suspensions for systemic action. The product must also meet the dissolution and excipient conditions. Narrow therapeutic index drugs and products absorbed through the oral mucosa are not eligible, and Class II and IV substances need an in vivo study.

What is the difference between a BCS biowaiver and an additional-strength biowaiver?

A BCS-based biowaiver replaces the in vivo study altogether, relying on the solubility and permeability of the substance and on in vitro dissolution. An additional-strength biowaiver still needs an in vivo study on one strength and extends its result to the others on the basis of proportional composition and similar dissolution, so it is open to substances of any BCS class.

What dissolution results does a BCS biowaiver need?

Test and reference are compared at pH 1.2, 4.5 and 6.8. For Class III substances both products must be very rapidly dissolving, at least 85% in 15 minutes. For Class I they must be very rapidly dissolving, or rapidly dissolving, at least 85% in 30 minutes, with similar profiles shown by an f2 value of 50 or more.

Sources

  1. European Medicines Agency: ICH M9 guideline on biopharmaceutics classification system-based biowaivers
  2. European Medicines Agency: Investigation of bioequivalence, scientific guideline
  3. European Medicines Agency: ICH M13B guideline on bioequivalence for immediate-release solid oral dosage forms, additional strengths biowaiver

Put your Biowaiver question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.